The Quiet Power of RGS Proteins: Rethinking Pain Pathways through GPCR Biology

Watch Episode 170

What We’re Missing in Pain Research

In GPCR drug discovery, receptors typically steal the spotlight. But as Dr. Alex Serafini pointed out in his interview, Regulators of G protein Signaling (RGS proteins) might hold some of the most untapped therapeutic opportunities, particularly in pain neuroscience.

Serafini described his connection to GPCRs as tangential but inevitable:

"I feel like I never was particularly explicitly interested in GPCR signaling... but the thing about GPCRs... is you always kind of end up landing at a GPCR as a major target."

His work in the lab of Dr. Venetia Zachariou introduced him to the power of RGS proteins — particularly RGS4 — in modulating pain circuits in ways that traditional targets fail to capture.

RGS4 and the Unexpected Recovery Phenomenon

One of the most compelling findings in Serafini’s experience was the spontaneous recovery observed in RGS4 knockout mice.

“There was this very interesting phenotype the lab found where, as a mouse was starting to enter what we consider the chronic pain range, the mice that were constitutively RGS4 knocked out started recovering spontaneously. And this is a recovery that is very rare to see at the preclinical level."

Such recovery is rare in preclinical pain models and hints that RGS proteins could modulate pain chronification itself. These findings suggest a path forward that isn’t about blocking a single receptor but about rewiring the entire system upstream of pain perception.

Serafini noted that RGS4 was especially intriguing because it was expressed robustly both in the peripheral nervous system and in central circuits like the prefrontal cortex and thalamus — areas deeply involved in both pain perception and affective comorbidities.

GPCRs in the Background, But Always Present

Even though his primary focus wasn’t GPCRs themselves, Serafini repeatedly encountered them as unavoidable players in pain-related pathways.

Whether working on opioid withdrawal, addiction vulnerability, or chronic pain, GPCR-related signaling repeatedly emerged as the core mediator — demonstrating the reach of these signaling pathways beyond classical receptor pharmacology.

This realization isn’t isolated. Serafini highlighted that in modern pain drug development, the field has remained too focused on ion channels like NAV1.8, despite these targets falling short clinically:

“The downstream cascade is probably a little bit weaker than if you were hitting a GPCR... and honestly, like with the trials, they were not really that sufficiently better than opioids, right? And in itself, that's kind of a suggestion.”

Takeaway

Forget what you think you know about GPCR drug targets. The real power may lie in how they’re regulated. Dr. Serafini’s work on RGS proteins suggests a quieter, but no less powerful, frontier in the fight against chronic pain.

___________

Keyword Cloud: RGS4, GPCR data platform, GPCR training program, pain research, opioid signaling.